StreetInsider.com News Articles

Third Arc Bio picks lead candidate in amended Adagene collaboration

Thu, 10 Sep 2026 08:03:06 -0400

Adagene Inc. (Nasdaq: ADAG) announced that Third Arc Bio, Inc. has selected its first lead candidate under an amended strategic licensing agreement between the two companies, according to a press release dated Sept. 10, 2026.

The original agreement, established in November 2025, allows Third Arc Bio to use Adagene's NEObody and SAFEbody technology platforms to develop masked CD3 T cell engagers targeting tumor-associated antigens.

Under the amended terms, the collaboration has been broadened. Third Arc Bio will sponsor and fund the clinical development of the selected program. In recognition of the expanded scope, the total potential payments to Adagene, including development and

Third Arc Bio picks lead candidate in amended Adagene collaboration

Thu, 10 Sep 2026 08:03:06 -0400

Form 6-K Adagene Inc. For: Sep 10

Thu, 10 Sep 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260910/27045446.html

Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology

Thu, 10 Sep 2026 08:00:00 -0400

Amended terms of agreement include a transition to an integrated asset and technology partnership.

SAN DIEGO and SUZHOU, China, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies today announced that Third Arc Bio, Inc. (“Third Arc Bio”) selected the first lead candidate under the amended strategic licensing agreement. The agreement was established in November 2025, under which Third Arc Bio utilizes Adagene’s NEObody® and SAFEbody® technology platform to generate masked CD3 T cell engagers against unique epitopes of

Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology

Thu, 10 Sep 2026 08:00:00 -0400

Amended terms of agreement include a transition to an integrated asset and technology partnership.

Chardan Starts Adagene Inc (ADAG) at Buy

Thu, 10 Sep 2026 06:33:20 -0400

Chardan analyst Gautam Chukka initiates coverage on Adagene Inc (NASDAQ: ADAG) with a Buy rating and a price target of $9.00.

For an analyst ratings summary and ratings history on Adagene Inc click here. For more ratings news on Adagene Inc click here.

Shares of Adagene Inc closed at $3.27 yesterday.

Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates

Wed, 09 Sep 2026 08:00:00 -0400

SAN DIEGO and SUZHOU, China, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced the achievement of a milestone in its ongoing collaboration and license agreement with Exelixis, Inc. (“Exelixis”).

The milestone achievement is related to a preclinical milestone event for XB404 and resulted in a $2.0 million milestone payment from Exelixis. XB404, built with Adagene’s SAFEbody masking technology, is designed to deliver a cytotoxic payload to ROR1/2-expressing tumors while minimizing on-target, off-tumor side effects. An additional

Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates

Wed, 09 Sep 2026 08:00:00 -0400

Form 144/A Adagene Inc. Filed by: GU CHUNFANG

Thu, 20 Aug 2026 18:12:00 -0400

si-local-file:///var/storage/secattach/20260820/26957366.html

Form 144/A Adagene Inc. Filed by: GU CHUNFANG

Thu, 20 Aug 2026 18:12:00 -0400

si-local-file:///var/storage/secattach/20260820/26957366.html

Adagene to Participate in Three Upcoming Investor Conferences

Thu, 20 Aug 2026 08:00:00 -0400

SAN DIEGO and SUZHOU, China, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (Nasdaq: ADAG) a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced that senior management will participate in three upcoming investor conferences taking place in New York, New York.

2026 Cantor Global Healthcare Conference; New York, NY – September 9-11, 2026

Format: 1x1 Meetings
Date/Time: September 11, 2026

Morgan Stanley 24th Annual Global Healthcare Conference; New York, NY – September 14-16, 2026

Format: Fireside Chat and 1x1 Meetings
Fireside Chat Date/Time: September 15, 2026,

Adagene to Participate in Three Upcoming Investor Conferences

Thu, 20 Aug 2026 08:00:00 -0400

2026 Cantor Global Healthcare Conference; New York, NY – September 9-11, 2026

Format: 1x1 Meetings
Date/Time: September 11, 2026

Morgan Stanley 24th Annual Global Healthcare Conference; New York, NY – September 14-16, 2026

Format: Fireside Chat and 1x1 Meetings
Fireside Chat Date/Time: September 15, 2026,

Adagene to Participate in Three Upcoming Investor Conferences

Thu, 20 Aug 2026 08:00:00 -0400

2026 Cantor Global Healthcare Conference; New York, NY – September 9-11, 2026

Format: 1x1 Meetings
Date/Time: September 11, 2026

Morgan Stanley 24th Annual Global Healthcare Conference; New York, NY – September 14-16, 2026

Format: Fireside Chat and 1x1 Meetings
Fireside Chat Date/Time: September 15, 2026,

Adagene to Participate in Three Upcoming Investor Conferences

Thu, 20 Aug 2026 08:00:00 -0400

2026 Cantor Global Healthcare Conference; New York, NY – September 9-11, 2026

Format: 1x1 Meetings
Date/Time: September 11, 2026

Morgan Stanley 24th Annual Global Healthcare Conference; New York, NY – September 14-16, 2026

Format: Fireside Chat and 1x1 Meetings
Fireside Chat Date/Time: September 15, 2026,

Form 144 Adagene Inc. Filed by: GU CHUNFANG

Wed, 19 Aug 2026 10:22:00 -0400

si-local-file:///var/storage/secattach/20260819/26948419.html

Form 144 Adagene Inc. Filed by: GU CHUNFANG

Wed, 19 Aug 2026 10:22:00 -0400

si-local-file:///var/storage/secattach/20260819/26948419.html

Form 4 Adagene Inc. For: Aug 14 Filed by: DO CUONG V

Tue, 18 Aug 2026 18:11:00 -0400

si-local-file:///var/storage/secattach/20260818/26945740.html

Form 4 Adagene Inc. For: Aug 14 Filed by: DO CUONG V

Tue, 18 Aug 2026 18:11:00 -0400

si-local-file:///var/storage/secattach/20260818/26945740.html

Form 4 Adagene Inc. For: Aug 13 Filed by: Zhu Li

Mon, 17 Aug 2026 20:32:00 -0400

si-local-file:///var/storage/secattach/20260817/26939335.html

Form 4 Adagene Inc. For: Aug 13 Filed by: Zhu Li

Mon, 17 Aug 2026 20:32:00 -0400

si-local-file:///var/storage/secattach/20260817/26939335.html

Form 4 Adagene Inc. For: Aug 13 Filed by: Cheung Andy Yiu Leung

Mon, 17 Aug 2026 20:31:00 -0400

si-local-file:///var/storage/secattach/20260817/26939333.html

Form 4 Adagene Inc. For: Aug 13 Filed by: Cheung Andy Yiu Leung

Mon, 17 Aug 2026 20:31:00 -0400

si-local-file:///var/storage/secattach/20260817/26939333.html

Form 4 Adagene Inc. For: Aug 13 Filed by: DO CUONG V

Mon, 17 Aug 2026 20:30:00 -0400

si-local-file:///var/storage/secattach/20260817/26939331.html

Form 4 Adagene Inc. For: Aug 13 Filed by: DO CUONG V

Mon, 17 Aug 2026 20:30:00 -0400

si-local-file:///var/storage/secattach/20260817/26939331.html

Form SCHEDULE 13G/A Adagene Inc. Filed by: WuXi PharmaTech Healthcare Fund I L.P.

Fri, 14 Aug 2026 16:58:00 -0400

si-local-file:///var/storage/secattach/20260814/26932350.html